Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew H Ko

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Clinical Pharmacology and Therapeutics|December 21, 2024
Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS TrialAndrew H Ko, Do-Youn Oh, Janet Lau, et al.
The Oncologist|June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRASChristopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Journal of Gastrointestinal Cancer|January 23, 2014
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot studyNicholas Fidelman, Robert K Kerlan, Randall A Hawkins, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 31, 2020
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic CancerAndrew H Ko, Alexander C Jordan, Evan Tooker, et al.
The Oncologist|September 23, 2017
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER TrialAndrew H Ko, Patrick B Murphy, James D Peyton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineEdward P Balaban, Pamela B Mangu, Alok A Khorana, et al.
Annals of Surgical Oncology|June 15, 2024
Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic CancerPhoebe N Miller, Fernanda Romero-Hernandez, Lucia Calthorpe, et al.
Cancer Discovery|June 26, 2015
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary CarcinomasOliver A Zill, Claire Greene, Dragan Sebisanovic, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Clinical Pharmacology and Therapeutics|December 21, 2024
Investigational Use of Real-World Data as a Hybrid Control in Pancreatic Ductal Adenocarcinoma From the Randomized Phase Ib/II MORPHEUS TrialAndrew H Ko, Do-Youn Oh, Janet Lau, et al.
The Oncologist|June 9, 2017
A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRASChristopher H Lieu, Manuel Hidalgo, Jordan D Berlin, et al.
Journal of Gastrointestinal Cancer|January 23, 2014
90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot studyNicholas Fidelman, Robert K Kerlan, Randall A Hawkins, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Breast Cancer Research and Treatment|February 15, 2016
A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignanciesAmy Jo Chien, Alyson Cockerill, Craig Fancourt, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|July 31, 2020
Dual Targeting of Mesothelin and CD19 with Chimeric Antigen Receptor-Modified T Cells in Patients with Metastatic Pancreatic CancerAndrew H Ko, Alexander C Jordan, Evan Tooker, et al.
The Oncologist|September 23, 2017
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER TrialAndrew H Ko, Patrick B Murphy, James D Peyton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 2, 2016
Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice GuidelineEdward P Balaban, Pamela B Mangu, Alok A Khorana, et al.
Annals of Surgical Oncology|June 15, 2024
Long-Duration Neoadjuvant Therapy with FOLFIRINOX Yields Favorable Outcomes for Patients Who Undergo Surgery for Pancreatic CancerPhoebe N Miller, Fernanda Romero-Hernandez, Lucia Calthorpe, et al.
Cancer Discovery|June 26, 2015
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary CarcinomasOliver A Zill, Claire Greene, Dragan Sebisanovic, et al.
Pageof 10